Catheter Precision (VTAK) Q2 2026 earnings summary

Executive summary

• Completed acquisition of FLYTE, expanding into private aviation alongside cardiac electrophysiology segment.

• Product portfolio includes VIVO System and LockeT, both with expanded international reach and regulatory approvals.

• FLYTE provides regional private jet charter services, leveraging technology for customer acquisition and operational efficiency.

Financial highlights

• For the six months ended June 30, 2026: total revenues $1.45M, up from $0.36M year-over-year, driven by FLYTE acquisition.

• Net loss for the six months was $5.0M, improved from $9.5M in the prior year period.

• Gross profit for the six months was $0.49M, compared to $0.33M in the prior year.

• Cash and cash equivalents at June 30, 2026 were $0.6M; accumulated deficit reached $314.5M.

Outlook and guidance

• Management expects continued operating losses and negative cash flows for the foreseeable future.

• Additional capital is required to fund operations, service debt, and support both business segments.

• Substantial doubt exists about the ability to continue as a going concern over the next 12 months.